Pharmacoeconomics

Pharmacoeconomics

1. Definition, scope and rationale

• Pharmacoeconomics is the branch of health economics that identifies, measures and compares the costs (resources consumed) and consequences (clinical, economic, humanistic outcomes) of pharmaceutical products and services to the healthcare system and society (Padmaja 7e Ch.5, pp.73).
• Working definition: the science that compares the cost of various treatment modalities to the outcome, to determine which treatment is less expensive and at least as effective — a "value-for-money" approach (Padmaja 7e Ch.5, pp.73).
• It is a comparative discipline: a cost or outcome is meaningless in isolation — it acquires meaning only against a defined comparator (current standard practice, placebo/no treatment, or "best supportive care") (B&B Ch.5, pp.56).
• Stated goals of pharmacoeconomic research (Padmaja 7e Ch.5, pp.73):
  • To identify which healthcare alternative provides the best outcome for the money spent.
  • To improve allocation of finite funds across competing healthcare needs.
  • To incorporate quality of life into healthcare-policy decisions, not just survival.
• Driving rationale — resource scarcity: "Even the richest societies cannot satisfy the appetite of their citizens for health care" — resources are finite, demand is (almost) infinite, so rationing (explicit or concealed) is unavoidable in every health system (B&B Ch.2, pp.23).
• The relevant policy question is not whether there should be rationing but what form it should take and whether it should be explicit or concealed from the public (B&B Ch.2, pp.23).
• Pharmacoeconomics provides a planned, transparent, fair basis for resource division, replacing distribution by an "unregulated power struggle" between professional and patient pressure groups (B&B Ch.2, pp.23).
• The prescriber is unavoidably an economic agent: "Money spent on prescribing is not available for another purpose" — every prescription is a resource-allocation (rationing) decision (B&B Ch.2, pp.24).
• Within drug regulation, pharmacoeconomics/HTA is often called the "fourth hurdle" — beyond the three licensing criteria of quality, safety and efficacy, a product must additionally demonstrate cost-effectiveness before adoption/reimbursement (B&B Ch.5, pp.56).
• The three core deliverables of an economic evaluation (B&B Ch.5, pp.56):
  • A systematic review of the clinical evidence.
  • An estimate of cost-effectiveness.
  • Conclusions on which decision-makers can act.
• Distinction — economic evaluation supports but does not supplant clinical judgement; it underpins evidence-based practice rather than replacing the decision-maker (B&B Ch.5, pp.61).
• Stakeholders/payers: doctors prescribe, patients consume, but increasingly third (purchasing) parties — governments, insurers — pay the bill, and they demand reliable absolute and relative cost-and-benefit data (B&B Ch.2, pp.23).
• A specialist workforce — health economists — generates these data; e.g. a PricewaterhouseCoopers report estimated each £1 spent on additional NHS clinical pharmacologists could reduce NHS costs by ≈£6 (B&B Ch.2, pp.24).